Cochrane for Clinicians
Putting Evidence into Practice
Antiviral Therapy for Bell Palsy
Am Fam Physician. 2016 May 1;93(9):742-743.
Author disclosure: No relevant financial affiliations.
Are antivirals effective therapy for Bell palsy?
The combination of antiviral agents and corticosteroids is more effective than corticosteroids alone for the complete recovery of patients with Bell palsy (number needed to treat [NNT] = 15) and for the resolution of motor synkinesis and excessive tear production (NNT = 12). (Strength of Recommendation [SOR]: B, based on inconsistent or limited-quality patient-oriented evidence.) Antivirals should not be used alone to treat Bell palsy. (SOR: A, based on consistent, good-quality patient-oriented evidence.)
Untreated idiopathic facial paralysis, or Bell palsy, leaves up to 30% of patients with some level of permanent facial asymmetry or pain.1 Previous meta-analyses have demonstrated the effectiveness of corticosteroids at reducing the rate of long-term disability.2 Some evidence suggests that recurrent viral infections, including herpes simplex virus and varicella zoster virus, are common causes of Bell palsy. This review evaluated the effectiveness of antiviral agents alone or in combination with corticosteroids for the treatment of Bell palsy. An earlier version of this review, which included two low-quality studies judged to be at high risk of bias, concluded that the combination of antivirals and corticosteroids was no more effective than corticosteroids alone for the treatment of Bell palsy.3
This Cochrane review included 10 trials with a total of 2,280 participants. The authors used meta-analysis to compare several treatment regimens and a variety of outcomes. Complete recovery rates of facial nerve function in patients with Bell palsy were improved by treatment with corticosteroids plus antivirals vs. corticosteroids alone at six months (relative risk [RR] = 0.61; 95% confidence interval [CI], 0.39 to 0.97; NNT = 15 [95% CI, 10 to 200]; n = 1,315). A subgroup analysis of patients with severe Bell palsy (i.e., House-Brackmann index of 5 or 6 out of 6) found that more patients achieved complete recovery when the combination of antivirals and corticosteroids was used vs. corticosteroids alone (RR = 0.64; 95% CI, 0.41 to 0.99; n = 478).
The combination of corticosteroids and antivirals also improved long-term motor synkinesis and excessive tear production (so-called “crocodile tears”) over corticosteroids alone (RR = 0.56; 95% CI, 0.36 to 0.87; NNT = 12 [95% CI, 8 to 40]; n = 469]). Treatment with antivirals alone was associated with higher rates of residual symptoms vs. treatment with corticosteroids alone (RR = 1.52; 95% CI, 1.08 to 2.12; n = 472). The rate of adverse effects was similar among all of the treatments compared.
The results of this review differ slightly from another meta-analysis that found that the routine addition of antivirals to corticosteroid therapy did not improve at least partial recovery.4 In that meta-analysis, the authors found that adding antivirals to corticosteroid therapy benefits only patients with severe Bell palsy. In subgroup analyses, the type of antiviral administered did not change outcomes. However, this meta-analysis included only one-half as many patients as the current Cochrane review, which may have led to a lack of statistical power.
Guidelines on Bell palsy from the American Academy of Otolaryngology–Head and Neck Surgery Foundation currently recommend prescribing oral corticosteroids within 72 hours of symptom onset (grade A) and recommend against the use of antiviral monotherapy (grade A).5 These guidelines state that physicians may opt to prescribe antiviral therapy in addition to corticosteroid therapy (option, grade B) because studies do not exclude a small effect. The American Academy of Neurology provides similar recommendations, stating that physicians should routinely prescribe corticosteroids to patients with Bell palsy and that they may consider offering antivirals in addition, although there may be no benefit (level C).6
Gagyor I, Madhok VB, Daly F, et al. Antiviral treatment for Bell's palsy (idiopathic facial paralysis). Cochrane Database Syst Rev. 2015;( 11): CD001869.
The practice recommendations in this activity are available at http://summaries.cochrane.org/CD001869.
editor's note: The numbers needed to treat reported in this Cochrane for Clinicians were calculated by the AFP medical editors based on raw data provided in the original Cochrane review.
The views expressed in this article are those of the authors and do not reflect the official policy or position of the U.S. government, the Department of the Army, or the Department of Defense.
REFERENCESshow all references
1. Peitersen E. The natural history of Bell's palsy. Am J Otol. 1982;4(2):107–111....
2. Salinas RA, Alvarez G, Daly F, Ferreira J. Corticosteroids for Bell's palsy (idiopathic facial paralysis). Cochrane Database Syst Rev. 2010;(3):CD001942.
3. Lockhart P, Daly F, Pitkethly M, Comerford N, Sullivan F. Antiviral treatment for Bell's palsy (idiopathic facial paralysis). Cochrane Database Syst Rev. 2009;(4):CD001869.
4. Quant EC, Jeste SS, Muni RH, Cape AV, Bhussar MK, Peleg AY. The benefits of steroids versus steroids plus antivirals for treatment of Bell's palsy: a meta-analysis [published correction appears in BMJ. 2013;346:f151]. BMJ. 2009;339:b3354.
5. Baugh RF, Basura GJ, Ishii LE, et al. Clinical practice guideline: Bell's Palsy executive summary. Otolaryngol Head Neck Surg. 2013;149(5):656–663.
6. Gronseth GS, Paduga R. Evidence-based guideline update: steroids and antivirals for Bell palsy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2012;79(22):2209–2213.
These are summaries of reviews from the Cochrane Library.
This series is coordinated by Corey D. Fogleman, MD, Assistant Medical Editor.
A collection of Cochrane for Clinicians published in AFP is available at https://www.aafp.org/afp/cochrane.
Copyright © 2016 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
May 15, 2018
Access the latest issue of American Family Physician